.jpg)
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure NV (QURE) yesterday and set a price target of $70. The company’s shares closed yesterday at $55.87, close to its 52-week high of $59.45.
Amusa said:
“We believe the big biopharma M&A activity (AveXis, AAV-based GT space, unrated Sanofi’s acquisition of hemophilia- company Bioverativ for $11.6 billion, and the considerable partnering seen in hemophilia GT (e.g. unrated Pfizer and Spark, Pfizer and unrated Sangamo, unrated REGENXBIO), increase the chances of a uniQure acquisition. We urge investors to consider the business development activity above and consider that uniQure is unpartnered and the likely market leader in hemophilia B gene therapy. GMAPs: We leave open our still-alpha-generative long-QURE/short ONCE pair trade opened on 7 November 2016, when Spark shares were at $44.10 and uniQure shares were at $7.07.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 16.3% and a 48.9% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catalyst Biosciences Inc, and Voyager Therapeutics Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $66.20, representing a 18.5% upside. In a report issued on February 11, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.45 and a one-year low of $20.29. Currently, uniQure NV has an average volume of 412.4K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
